The utilization of a mAb anti-CD40, CP-870893, targets the non-ligand binding site of CD40, enhance the secretion of IL-12, IL-23, and IL-8 and in combination with gemcitabine, is associated with antitumor activity in pancreatic ductal carcinoma patients [215]. This evidence concerns the gene CD40 and pancreatic ductal adenocarcinoma.